US Stock MarketDetailed Quotes
SYRE Spyre Therapeutics
- 27.000
- -0.500-1.82%
Close Nov 21 16:00 ET
- 27.000
- 0.0000.00%
Post 16:20 ET
1.59BMarket Cap-9722P/E (TTM)
29.090High26.760Low820.95KVolume27.590Open27.500Pre Close22.33MTurnover2.04%Turnover RatioLossP/E (Static)58.71MShares47.97052wk High9.24P/B1.09BFloat Cap10.42052wk Low--Dividend TTM40.21MShs Float318.750Historical High--Div YieldTTM8.47%Amplitude2.650Historical Low27.199Avg Price1Lot Size
About Spyre Therapeutics Company
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.
Company Profile
SymbolSYRE
Company NameSpyre Therapeutics
Listing DateApr 7, 2016
Founded2013
CEODr. Cameron Turtle, D.Phil.
MarketNASDAQ
Employees30
Fiscal Year Ends12-31
AddressBuilding 17,221 Crescent Street,Suite 102B
CityWaltham
ProvinceMassachusetts
CountryUnited States of America
Zip Code02453
Phone1-617-651-5940
Websitehttp://www.spyre.com
Company Executives
- Name
- Position
- Salary
- Dr. Cameron Turtle, D.Phil.
- Director, President and Chief Executive Officer
- 15.92M
- Dr. Scott L. Burrows, M.D.
- Chief Financial Officer and Principal Accounting Officer
- 7.55M
- Heidy King-Jones
- Chief Legal Officer and Corporate Secretary
- 6.59M
- Jeffrey W. Albers, J.D.
- Chairman of the Board
- 433.57K
- Dr. Sandra Milligan, J.D.
- Director
- --
- Laurie D. Stelzer, M.B.A.
- Independent Director
- 434.38K
- Tomas Kiselak
- Independent Director
- 658.43K
- Mark C. McKenna
- Independent Director
- --
- Peter Harwin
- Independent Director
- 661.28K
- Dr. Michael Henderson, M.D.
- Independent Director
- --
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data